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Abstract
Introduction: Selection of the K103N mutation is associated with moderately reduced in vitro
fitness of HIV. Strains bearing K103N in vivo tend to persist, even in the absence of additional drug
pressure, as minority quasispecies, often undetectable in genotyping resistance testing assays,
performed at standard conditions. Here, we report on the rapid and long lasting selection of a K103N
bearing strain as the dominant quasispecies after very short exposure to efavirenz in vivo.
Case presentation: A 55-year-old Caucasian man was switched to efavirenz, zidovudine and
lamivudine in February 2003, while on viral suppression in his first-line highly active anti-retroviral
treatment regimen. One month later, he reported inconsistent adherence and his viremia level was
5700 c/mL. He did not attend further checkups until September 2005, when his viral load was
181,000 c/mL. The patient reported interrupting his medications approximately three weeks after
simplification. The genotyping resistance testing assay was performed both on HIV RNA and HIV
DNA from plasma, yielding an identical pattern with the isolate presence of the K103N mutation in
the prevalent strain.
Conclusion: Persistence of the K103N mutation as a majority quasispecies may ensue after a very
short exposure to efavirenz. Our case would therefore suggest that the presence of the K103N
mutation should always be ruled out by genotyping resistance testing assays, even after minimal
exposures to efavirenz.
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Non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based highly active anti-retroviral treatment (HAART)
regimens are characterized by a good tolerance of relatively
low levels of adherence to therapy, although resistance
selection may ensue when adherence drops below the
75% threshold [1,2]. First generation NNRTIs have a low
genetic barrier and the K103N mutation is able to confer
class resistance after selection [3,4]. As efavirenz (EFV) and
nevirapine (NVP) have a much longer plasma half-life
than their companion nucleoside reverse transcriptase
inhibitors (NRTIs), residual NNRTI monotherapies asso-
ciated with structured or non-structured therapy interrup-
tions may favor K103N selection. Although selection
of the K103N mutation is associated with moderately
but significantly reduced in vitro fitness [5], strains bearing
K103N in vivo tend to persist even in the absence of
additional drug pressure. K103N persistence, however, is
more frequently observed as a minority quasispecies, often
undetectable in GRT (Genotypic antiretroviral Resistance
Testing) assays performed at standard conditions.
A single dose of NVP administered during delivery in
pregnant women to prevent mother from transmitting HIV
to their babies was able to select K103N mutant strains,
which could persist as minority quasispecies for as long as
five years after drug exposure [6]. Persistence of NNRTI-
induced mutations, and particularly persistence of the
K103N mutation, has also been observed in patients on
treatment interruptions after failure of NNRTI-based
regimens, as well as in patients on failing protease
inhibitor (PI)-based regimens after previous NNRTI fail-
ures [7]. In this report, we describe the case of a 55-year-
old HIV-infected man, for whom a quickly selected and
long-term persisting K103N mutation was detected after
a time of exposure to EFV as short as three weeks. The
K103N bearing strain persisted as the dominant quasi-
species for over three years in the absence of any further
drug pressure, as documented by a GRT assay performed at
the end of a long-lasting treatment interruption.
Case presentation
A55-year-oldCaucasianmalepatientinfectedwithHIVfor
more than 10 years after heterosexual exposure, CDC class
Csince1999duetopneumocystisjirovecipneumonia,was
put on his first-line HAART regimen in November 1998,
with indinavir, zidovudine (AZT) and lamivudine (LMV).
His virological response was prompt and long lasting. Pre-
HAART viremia level was 215,000 c/mL (5,3Log10, no GRT
assay was performed at that time), pre-HAART CD4+
T-lymphocytes were 17/µL. After viral suppression, his
CD4+ T-cell counts very slowly improved, approaching the
200/µL threshold only after 28 months of treatment.
Therefore, his HAART scheme was not simplified, with no
signs of drug-related toxicity ensuing. In February 2003,
however, after approximately four years of treatment, the
patient declared his intention to change his treatment
drugs. According to the patient, he experienced treatment-
related fatigue and had recent adherence failures. His viral
load at that time, however, was still undetectable. His
treatment was therefore switched to EFV, AZT and LMV.
One month later, during his next scheduled control, his
viremia was 5700 c/mL (3,7 Log10); he reported incon-
sistent adherence. After that, he did not show up until
March 2006. He was hospitalized due to clinical progres-
sion (high fever and remarkable weight loss), with a
discharge diagnosis of disseminated atypical mycobacter-
iosis. On admission, CD4+ T-cell counts were 12/µL, and
his viral load was 181.000 c/mL (5,2 Log10). The patient
reported interruption of all his medications a few days
after his last check in 2003, approximately three weeks
after therapy simplification (Figure 1). Neither a pre-
NNRTI GRT assay was available at that time, nor samples
of plasma drawn in advance of the NNRTI-based
treatment, had been stored. GRT assays, however, were
performed both on HIV RNA and on HIV DNA from
peripheral blood. These proved that HIV infection was due
to clade B HIV-1, both yielding an identical sequence
pattern, with the isolate presence of the K103N mutation
in the prevalent strain (Table 1). The patient was put on a
new PI-based HAART regimen including boosted atazana-
vir, tenofovir and emtricitabine, reaching a prompt and
complete (<40 c/mL) viral suppression after two weeks.
Discussion
Assuming that HIV replication relapsed seven to 14 days
after interruption of the EFV-containing HAART regimen,
our patient was likely exposed to a residual monotherapy
with EFV for some one to two weeks, as pharmacokinetics
data on EFV indicate a serum half-life of 14.6-167.6 hours,
significantlylongerthanthatofAZT(1to2hours)andLMV
(8 hours). Furthermore, chromatographic assays for EFV,
performedsevendaysafterthelastdose,demonstratedsub-
therapeutic concentrations of EFV in plasma (70-720 ng/
mL) [8]. A GRT had not been performed at the time of first
HIV diagnosis, so straightforward evidence could not be
providedtoexcludethepresenceoftheK103Nmutationin
our patient in advance of his first line HAART.
He first presented in our ward in 2000, with very advanced
HIV infection (Nadir CD4 counts = 15/mm
3) and pneumo-
cystis jiroveci pneumonia. He never travelled abroad, and
reported risky heterosexual behaviors up to some 10 years
before presentation. As a consequence, although both the
existence [9] and the transmission [10] of HIV strains
carrying the K103N mutation in NNRTI-naïve patients have
been extensively documented, it is unlikely that our patient
may have been infected with an HIV strain carrying the
K103N mutation, as the widespread use of NNRTIs in Italy
Page 2 of 5
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:9132 http://jmedicalcasereports.com/jmedicalcasereports/article/view/9132began after 1996. Therefore, it is more likely that exposure
to EFV monotherapy at the time of therapy interruption
selected the K103N mutation, which persisted as the
prevalent quasispecies for over 3 years of continual viral
replication, in the absence of selective pressure.
Our experience is therefore very similar to the observed
scenarioofHIV-infectedwomenexposedtoasingledoseof
NVP for prevention of mother-to-child HIV transmission.
Reportsonsuchwomen, however,indicatethattheK103N
quasispecies were present as a minority quasispecies in
mostdescribedcases[6,11,12].Similarly,bymeansofhigh
sensitivitysequencingtechniques,Palmeretal.reportedon
the persistence of K103N mutation after EFV interruption
in patients failing to EFV-containing regimens, document-
ing variable decay kinetics for the K103N containing
quasispecies. Such quasispecies most frequently decayed
and disappeared after a few weeks, but less frequently so,
after a few months. In one patient, strains carrying K103N
mutation persisted for six years as dominant quasispecies,
in the absence of selective pressure, after administration of
EFV for a year and a half. In such a case, the authors
postulated a possible eradication of the wild type quasis-
peciesbeforeHAARTfailure[13].Capettietal.reportedthe
case of a HIV-infected woman who, seven years after
exposure to a failing loviride-containing HAART regimen,
presented the K103N mutation at a later viral relapse,
without further exposure to any NNRTI selective pressure
for as long as seven years after loviride. This patient,
however,hadbeenkeptunderprolonged viral suppression
on protease inhibitor (PI)-containing HAART regimens,
likely limiting viral replicative competition [14]. In our
patient, persistence of the K103N-containing quasispecies
ensued after a short exposure to EFV, in the absence of any
furtherselectivepressure.Therefore,itlikelydependedona
relatively small decrease in viral fitness of this prevalent
quasispecies relative to wild type.
It is now well-known that NNRTIs bind a hydrophobic site
adjacent with the enzyme active site of HIV reverse
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Figure 1. Human immunodeficiency virus viremia, CD4+ T-cell counts and therapy during follow-up (3TC Lamivudine, AZT
Zidovudine, ATV Atazanavir, IDV Indinavir, EFV Efavirenz, TDF Tenofovir, FTC Emtricitabine, GRT Genotyping Resistance
Testing).
Table 1. GRT of proviral and plasma HIV, as interpreted by the Stanford
HIV database algorithm (as of March, 2006)
HIV-DNA resistance
mutations
HIV-RNA resistance
mutations
PI Major Resistance
Mutations:
None None
PI Minor Resistance
Mutations:
L10V None
PI Other Mutations: I15V V11FV
R41K E35D
L63P N37NS
R41K
P44LP
R57K
L63P
G94GRS
NRTI Resistance
Mutations:
None None
NNRTI Resistance
Mutations:
K103N K103N
RT Other Mutations: K64R
R211K
V245Q
K30Q, K32GRS,
A33C, L34T, V35L,
E36N, I37F, K46KT,
V148EV, Q174LQ,
R211K, V245Q
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active site influencing enzyme performance [15]. Collins
et al., applied a fitness assay to several NNRTI drug-
resistant quasispecies, demonstrating that the wild type
had a better fitness than K103N-bearing quasispecies, and
that the fitness rank for other NNRTI mutation-carrying
quasispecies was 181C > 190A > 188C > 106A.
Furthermore, they demonstrated that double and triple
NNRTI mutation-carrying quasispecies had worse fitness
than single mutation carrying quasispecies [5]. Along a
different line of evidence, Hatano et al. recently demon-
strated that failing NNRTI-based HAART regimens do not
confer clinical residual advantage, at variance with PI-
based failing HAART regimens. This observation would
suggest that unlike PI-induced mutations, NNRTI-induced
mutations do not significantly alter fitness of mutation-
carrying quasispecies [16].
This scenario confirms the result of Fox et al. 2008, and
highlights the need to interrupt NNRTI-based regimens
wisely. Patients of the SMART study interrupting NNRTI-
based regimens restarted later on the same regimen. Fox
et al. demonstrated that patients on staggered interrup-
tions (interruption of NRTIs one week after that of the
NNRTI) or switched interruptions (replacement of the
NNRTI with a boosted PI for a short period) of all drugs
were less likely than those using simultaneous interrup-
tions to have any NNRTI mutation in their GRT performed
two months following the treatment interruption. They
also demonstrated that patients who carried a NNRTI-
mutation after the interruption achieved viral resuppres-
sion significantly less frequently than those who did not
have any mutation in their resistance test [17].
Conclusion
Our experience, although similar to that reported by
Palmer et al. on one of their patients, would indicate that
persistence of the K103N mutation as a majority
quasispecies may ensue after a very short exposure to
EFV, in the absence of wild type depletion, likely providing
relative replicative advantage.
Our case therefore suggests that the presence of the K103N
mutation should be ruled out even after minimal
exposures to EFV, reinforcing at the same time the need
for a systematic evaluation of GRT in naïve patients and
after any type of interruption of NNRTI-based HAART
regimens, as well as the need for a wise strategy of NNRTI
interruption.
Abbreviations
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